EU First, US Second For Product Launch? Not Necessarily, Says French Investor
This article was originally published in The Gray Sheet
Executive Summary
As US medical device regulations moderate and EU regulations start to become more stringent, companies have a harder decision to make about which of the two markets they should target for initial launch of their products, says Thierry Chignon, senior partner at Mérieux Développement.
You may also be interested in...
EU Policy-Makers Set End-Of-Year Goal To Finalize Device, Dx Reform
The first of five "trilogue" meetings between the European Parliament, the Council of the European Union and the European Commission to reach a settlement on broad-reaching EU device and diagnostics regulatory reforms took place Oct. 13
Sanofi Clinches Key Phase III Immunology Win With Rilzabrutinib
Sanofi’s BTK inhibitor – one of two from its 2021 Principia buy – passed a Phase III test in immune thrombocytopenia as the company focuses on Dupixent-like blockbusters going forward.
US FDA Gene Therapy Accelerated Approval Guidance Will Describe ‘Buckets’ Of Use Scenarios
Forthcoming guidance is expected to describe areas of “low-hanging fruit” and those that are more challenging for use of the expedited pathway, Center for Biologics Evaluation and Research Director Peter Marks said.